Global Health Opportunity Varespladib enables immediate bite-time administration, creating a compelling pre-hospital rescue option for snakebite. Given the global burden of 4-5 million bites annually and high mortality before hospital arrival, partnerships with NGOs, ministries of health, international bodies, and humanitarian programs offer scalable routes to broad distribution in remote and low-resource settings.

Veterinary Market Developing for use in dogs opens a large veterinary market, including emergency clinics, veterinary networks, and pet insurers. This creates opportunities to pitch through veterinary distributors and practice groups in both the United States and high-incidence regions, complementing human-use channels and expanding the addressable market.

Defense Partnerships Defense Health Agency funding and involvement point to military and allied-force procurement channels as a viable sales path. Opportunities exist to integrate field-ready formulations for envenomation response, targeting military medical logistics, disaster response programs, and federal procurement networks.

Strategic Collaborations Recent collaboration activity, such as the Lstmed agreement to produce marimastat for LSTM, alongside Wellcome Trust support, demonstrates a productive network of research and development partnerships. Leverage these relationships to access distribution partners, contract research organizations, and regional health agencies that can accelerate adoption.

Growth Momentum Solid funding and revenue trajectory signal scalable growth potential and manufacturing readiness. The company’s public benefit status and investor backing, including a Series B and notable grants, support credibility when engaging with large health systems, public sector buyers, and international distributors.